Desloratadine Production Not Anticipated In Loratadine Patent – Schering
This article was originally published in The Tan Sheet
Executive Summary
A compound does not need to be explicitly described in writing to be inherently anticipated by a patent, a Federal Circuit judge told Schering-Plough April 8
You may also be interested in...
Generic Claritin Does Not Infringe Schering Patent - Appeals Court
The Aug. 1 decision by a Washington D.C. federal appeals court finding certain loratadine patent claims invalid "does not preclude patent protection for metabolites of known drugs," the judges write
Generic Claritin Does Not Infringe Schering Patent - Appeals Court
The Aug. 1 decision by a Washington D.C. federal appeals court finding certain loratadine patent claims invalid "does not preclude patent protection for metabolites of known drugs," the judges write
Generic Claritin Does Not Infringe Schering Patent - Appeals Court
The Aug. 1 decision by a Washington D.C. federal appeals court finding certain loratadine patent claims invalid "does not preclude patent protection for metabolites of known drugs," the judges write